MIST Milestone Pharmaceuticals Inc.
USHealthcareAs of 2026-07-10 16:00
Why MIST matters now
Milestone Pharmaceuticals Inc. (MIST) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.28 with -2.29% on the session and $109.9M in market capitalization; recent performance reads 1-month -9.09% and YTD -35.64%.
The latest financial table shown here is Q1 2026, with revenue of $238.0K, net income of $-26.1M, and EPS of $-0.20. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -45.9%.
The latest indexable market news headline is "Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)" from Globe News Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $6.00; recent insider activity includes PAPA JOSEPH C filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.70
P/S
62.59
EV/EBITDA
-2.90
DCF Value
$0.15
FCF Yield
-45.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
94.7%
Operating Margin
-3669.4%
Net Margin
-3832.0%
ROE
-339.4%
ROA
-35.3%
ROIC
-37.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $238.0K | $-26.1M | $-0.20 |
| Q4 2025 | $1.5M | $-17.4M | $-0.16 |
| FY 2025 | $1.5M | $-63.1M | $-0.75 |
| Q3 2025 | $0.00 | $-11.9M | $-0.12 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$6.00
Target (Median)
$6.00
Target Range
$6.00 - $6.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
CA
Exchange
—
Beta
0.96
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.